Enanta Pharmaceuticals | ENTA - Equity Capital And Reserves


Enanta Pharmaceuticals reported $126.59M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -3.27B 628M Dec/2025
Amgen USD 9.19B 532M Mar/2026
Anika Therapeutics USD 133.9M 9.56M Mar/2026
Arrowhead Research USD 568.42M 102.37M Dec/2025
AstraZeneca USD 47.33B 1.33B Mar/2026
BioCryst Pharmaceuticals USD -119.15M 268.74M Dec/2025
Biogen USD 18.65B 394.9M Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Halozyme Therapeutics USD 48.81M 455.1M Dec/2025
Heron Therapeutics USD 13.28M 1.6M Dec/2025
Immunic USD -6.67M 17.17M Dec/2025
Incyte USD 5.62B 455.37M Mar/2026
Insmed USD 738.98M 206.6M Dec/2025
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
J&J USD 81.19B 358M Mar/2026
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
Ligand Pharmaceuticals USD 1.02B 67.04M Dec/2025
Merck USD 45.88B 6.73B Mar/2026
Neurocrine Biosciences USD 3.41B 154.3M Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Novavax USD -127.75M 28.92M Dec/2025
Pfizer USD 90.1B 3.63B Mar/2026
PTC Therapeutics USD -205.31M 49.56M Dec/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026